- Home
- PRGS vs HCM Comparison
PRGS vs HCM Comparison
Compare PRGS & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGS
- HCM
- Stock Information
- Founded
- PRGS 1981
- HCM 2000
- Country
- PRGS United States
- HCM Hong Kong
- Employees
- PRGS N/A
- HCM N/A
- Industry
- PRGS Computer Software: Prepackaged Software
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PRGS Technology
- HCM Health Care
- Exchange
- PRGS Nasdaq
- HCM Nasdaq
- Market Cap
- PRGS 2.4B
- HCM 2.6B
- IPO Year
- PRGS 1991
- HCM N/A
- Fundamental
- Price
- PRGS $51.39
- HCM $15.25
- Analyst Decision
- PRGS Buy
- HCM Hold
- Analyst Count
- PRGS 8
- HCM 1
- Target Price
- PRGS $72.13
- HCM $19.00
- AVG Volume (30 Days)
- PRGS 663.5K
- HCM 84.4K
- Earning Date
- PRGS 03-31-2025
- HCM 03-19-2025
- Dividend Yield
- PRGS 0.68%
- HCM N/A
- EPS Growth
- PRGS N/A
- HCM N/A
- EPS
- PRGS 1.54
- HCM 0.04
- Revenue
- PRGS $753,409,000.00
- HCM $630,201,000.00
- Revenue This Year
- PRGS $30.56
- HCM $28.98
- Revenue Next Year
- PRGS $3.29
- HCM $20.41
- P/E Ratio
- PRGS $33.47
- HCM $69.52
- Revenue Growth
- PRGS 8.49
- HCM N/A
- 52 Week Low
- PRGS $48.00
- HCM $12.84
- 52 Week High
- PRGS $70.56
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- PRGS 31.95
- HCM 50.03
- Support Level
- PRGS $53.74
- HCM $14.00
- Resistance Level
- PRGS $55.74
- HCM $16.64
- Average True Range (ATR)
- PRGS 1.32
- HCM 0.47
- MACD
- PRGS -0.16
- HCM -0.12
- Stochastic Oscillator
- PRGS 0.81
- HCM 47.35
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.